Lp-PLA₂ Activity

Plaque risk is partly about how many ApoB and LDL particles reach the artery wall. It is also about what happens once they get there. Lp-PLA2 activity is a blood test for one enzyme linked to that artery-wall inflammatory process.

Higher activity tracks with a higher chance of coronary heart disease. Its link with ischemic stroke is weaker and less certain for the activity test specifically. The test is more artery-focused than hs-CRP, and the activity number is unusually stable from draw to draw. It is an add-on risk marker, not a stand-alone diagnosis or a treatment target.

What the Enzyme Actually Does

Lp-PLA2 is short for lipoprotein-associated phospholipase A2. In blood, most of this enzyme travels attached to LDL particles. LDL is the main cholesterol-rich particle family involved in plaque buildup. The activity test measures how much work the enzyme is doing, not just how much enzyme protein is present.

Inflammatory cells in plaque make Lp-PLA2. The enzyme breaks down chemically altered fats in LDL and releases byproducts that can irritate the vessel wall. That is why a high activity reading is best read as a signal of vascular inflammation, not whole-body inflammation.

Heart Attack and Coronary Disease Risk

The strongest activity-specific evidence comes from a pooled analysis of 32 studies and 79,036 adults. Each standard-sized increase in activity carried about 10% higher coronary heart disease risk and about 16% higher risk of dying from a vascular cause. These links held after accounting for age, sex, smoking, blood pressure, diabetes, and cholesterol. The relationship was steady across the range, not a sudden jump at one cutoff.

A later general-population review pooled studies of activity and mass for its top-vs-bottom comparison. The highest Lp-PLA2 groups had about 1.5 times the coronary heart disease risk of the lowest. That figure is useful for scale, but it is not activity-only.

A high activity reading is a reason to look harder at heart-disease risk than LDL cholesterol alone might suggest. The point is not to chase this enzyme. The point is to check whether the main drivers of plaque, ApoB, LDL cholesterol, Lp(a), blood pressure, blood sugar, smoking, and inflammation, are being handled aggressively enough.

Stroke Risk

The stroke signal is weaker for activity than for coronary disease. In the 32-study collaboration, activity's link with ischemic stroke was smaller and did not reach statistical significance, unlike its clear link with coronary disease. A later review that pooled activity and mass found people in the highest Lp-PLA2 categories had roughly 60% higher ischemic stroke risk than those in the lowest, but that figure mixes the two tests rather than isolating activity.

ARIC measured Lp-PLA2 mass, a related but different measurement. In that cohort, hs-CRP and Lp-PLA2 barely correlated. When both were high, ischemic stroke risk was more than eleven times higher than when both were low. The pair can be useful because one marker is broad and the other is more vessel-focused.

The Puzzle: Predictive but Not a Lever

The part that trips people up is darapladib. This drug was built to block Lp-PLA2. It cut enzyme activity sharply, but two large randomized trials did not show fewer major coronary events. Large genetic studies found the same pattern: people born with lower Lp-PLA2 activity were not protected from coronary heart disease in the way a causal drug target would predict.

These facts fit if you treat Lp-PLA2 activity as a warning light. The enzyme travels on LDL particles and is concentrated around inflamed plaque, so it reports on a process that is already active. A high reading tells you to work on the drivers with proven outcome data, especially ApoB and LDL particle burden, instead of trying to block the enzyme itself.

A Stable Marker

Lp-PLA2 activity changes less within a person than many inflammation markers. In healthy adults, more than 90% of the measured variation came from differences between people, and average within-person swings were small across daily, weekly, and monthly testing. Fasting did not materially change the result.

That stability makes repeat testing easier to interpret when something real changes, such as starting lipid-lowering treatment or losing weight. In the variability study, a shift of about 17% was the rough line where a change was more likely to be real than lab noise.

When Results Can Be Misleading

A few situations can push this number in a way that misleads you:

• Recent heart attack or stroke: after an acute heart attack or stroke, Lp-PLA2 mass and activity can drop for days to weeks, so an early reading can understate your baseline. Wait until you have recovered before treating it as your usual level.
• Reduced kidney function: chronic kidney disease can raise Lp-PLA2 mass and activity, so an elevated result may partly reflect kidney-related inflammation and lipoprotein changes.
• Statins and other lipid-lowering drugs: these genuinely lower the number. A normal-looking result on treatment reflects the medication effect, not necessarily a low-inflammation artery wall.
• Assay type: activity and mass are related but not interchangeable. If you are trending results, compare activity with activity from the same lab method when you can.
• Who you are: activity differs by sex and ancestry, so a single fixed cutoff may fit some groups better than others. Your own trend and your other risk markers matter more.

What an Elevated Result Should Make You Do

First, make sure the reading is clean: not drawn soon after an acute event, and interpreted with kidney function and lipid-lowering medication in mind. If it holds up, treat it as a prompt to build a fuller picture rather than to fixate on the enzyme.

Order or review the markers that actually drive plaque: ApoB and LDL cholesterol for particle burden, Lp(a) for inherited risk, and hs-CRP for the broader inflammation angle. If Lp-PLA2 activity and hs-CRP are both high, treat them as two separate warning signals rather than one duplicated finding. A coronary calcium scan can show whether plaque is already present. If several markers line up against you, a cardiologist or lipid specialist can help set lower ApoB and LDL targets and decide whether imaging or medication changes make sense.